Lopez-Muňoz, F, Alamo, C, Cuenca, E, Shen, WW, Clervoy, P, Rubio, G. History of the discovery and clinical introduction of chlorpromazine. Ann Clin Psychiatry
2005; 17: 113–35.
Shepherd, M. Neurolepsis and the psychopharmacological revolution: myth and reality. Hist Psychiatry
1994; 5: 89–96.
Hillert, A, Sandmann, J, Ehmig, SC, Sobota, K, Weisbecker, W, Kepplinger, HM, et al. Psychopharmacological drugs as represented in the press: results of systematic analysis of newspapers and popular magazines. Pharmacopsychiatry
1996; 29: 67–71.
Trollor, JN, Chen, X, Chitty, K, Sachdev, PS. Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics. Br J Psychiatry
2012; 201: 52–6.
Cowen, PJ. Has psychopharmacology got a future?
Br J Psychiatry
2011; 198: 333–5.
Adachi, N, Akanuma, N, Ito, M, Kato, M, Hara, T, Oana, Y, et al. Epileptic, organic and genetic vulnerabilities for timing of the development of interictal psychosis. Br J Psychiatry
2010; 196: 212–6.
Henquet, C, van Os, J, Kuepper, R, Delespaul, P, Smits, M, Campo, JA, et al. Psychosis reactivity to cannabis use in daily life: an experience sampling study. Br J Psychiatry
2010; 196: 447–53.
Craddock, N, Owen, MJ. Molecular genetics and the relationship between epilepsy and psychosis. Br J Psychiatry
2010; 197: 75–6.
Shah, J, Mizrahi, R, McKenzie, K. The four dimensions: a model for the social aetiology of psychosis. Br J Psychiatry
2011; 199: 11–4.
Staring, ABP, Van der Gaag, M, Koopmans, GT, Selten, JP, Van Beveren, JM, Hengeveld, MW, et al. Treatment adherence therapy in people with psychotic disorders: randomised controlled trial. Br J Psychiatry
2010; 197: 448–55.
Burns, T, Yeeles, K, Molodynski, A, Nightingale, H, Vazquez-Montes, M, Sheehan, K, et al. Pressures to adhere to treatment (‘leverage’) in English mental healthcare. Br J Psychiatry
2011; 199: 145–50.
Tyrer, P. From the Editor's desk. Br J Psychiatry
2011; 199: 262.